Literature DB >> 18276597

Bruton's tyrosine kinase separately regulates NFkappaB p65RelA activation and cytokine interleukin (IL)-10/IL-12 production in TLR9-stimulated B Cells.

Koon-Guan Lee1, Shengli Xu, Ee-Tsin Wong, Vinay Tergaonkar, Kong-Peng Lam.   

Abstract

B lymphocytes express both B cell receptor and Toll-like receptors (TLR). We show here that Bruton's tyrosine kinase (Btk), a critical component in B cell receptor signaling, is also involved in TLR9 signaling in B cells. Stimulation of B cells with TLR9 ligand CpG oligodeoxynucleotide (ODN) leads to transient phosphorylation of Btk, and in the absence of Btk, TLR9-induced proliferation of B cells is impaired. Interestingly, Btk(-/-) B cells secrete significantly more interleukin (IL)-12 but much less IL-10 compared with wild type B cells upon TLR9 stimulation. Immunization of Btk(-/-) mice with CpG ODN also leads to elevated levels of IL-12 in vivo and consequently, a greater -fold increment in the production of Th1 type IgG2b and IgG3 antibodies in these mice compared with wild type controls. The addition of exogenous recombinant IL-10 could suppress IL-12 production by TLR9-activated Btk(-/-) B cells, suggesting that in B cells, Btk negatively regulates IL-12 through the induction of autocrine IL-10 production. TLR9 signaling also leads to the activation of NFkappaB, including the p65RelA subunit in wild type B cells. The lack of Btk signaling affects the activation of NFkappaB and impairs the translocation of the p65RelA subunit to the nucleus of B cells upon TLR9 stimulation. However, p65RelA(-/-) B cells could respond similarly to wild type B cells in terms of IL-10 and IL-12 secretion when stimulated with CpG ODN, suggesting that the defect in NFkappaB p65RelA activation is additional to the impairment in cytokine production in TLR9-activated Btk(-/-) B cells. Thus, Btk plays an important role in TLR9 signaling and acts separately to regulate NFkappaB RelA activation as well as IL-10 and IL-12 production in B cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18276597     DOI: 10.1074/jbc.M708516200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  33 in total

1.  Increased pro-inflammatory cytokine production after lipopolysaccharide stimulation in patients with X-linked agammaglobulinemia.

Authors:  María Edith González-Serrano; Iris Estrada-García; Dolores Mogica-Martínez; Alejandro González-Garay; Gabriela López-Herrera; Laura Berrón-Ruiz; Sara Elva Espinosa-Padilla; Marco Antonio Yamazaki-Nakashimada; Alexander Vargas-Hernández; Leopoldo Santos-Argumedo; Sergio Antonio Estrada-Parra; Francisco J Espinosa-Rosales
Journal:  J Clin Immunol       Date:  2012-06-05       Impact factor: 8.317

2.  Targeting Bruton's tyrosine kinase signaling as an emerging therapeutic agent of B-cell malignancies.

Authors:  Bing Xia; Fulian Qu; Tian Yuan; Yizhuo Zhang
Journal:  Oncol Lett       Date:  2015-10-13       Impact factor: 2.967

3.  The role of Bruton's tyrosine kinase in the development and BCR/TLR-dependent activation of AM14 rheumatoid factor B cells.

Authors:  Kerstin Nündel; Patricia Busto; Michelle Debatis; Ann Marshak-Rothstein
Journal:  J Leukoc Biol       Date:  2013-06-26       Impact factor: 4.962

Review 4.  Toll-like receptors--sentries in the B-cell response.

Authors:  Isabelle Bekeredjian-Ding; Gaetan Jego
Journal:  Immunology       Date:  2009-11       Impact factor: 7.397

Review 5.  Tyrosine phosphorylation in Toll-like receptor signaling.

Authors:  Saurabh Chattopadhyay; Ganes C Sen
Journal:  Cytokine Growth Factor Rev       Date:  2014-06-21       Impact factor: 7.638

6.  The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation.

Authors:  Sean D Reiff; Rose Mantel; Lisa L Smith; J T Greene; Elizabeth M Muhowski; Catherine A Fabian; Virginia M Goettl; Minh Tran; Bonnie K Harrington; Kerry A Rogers; Farrukh T Awan; Kami Maddocks; Leslie Andritsos; Amy M Lehman; Deepa Sampath; Rosa Lapalombella; Sudharshan Eathiraj; Giovanni Abbadessa; Brian Schwartz; Amy J Johnson; John C Byrd; Jennifer A Woyach
Journal:  Cancer Discov       Date:  2018-08-09       Impact factor: 39.397

7.  Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies.

Authors:  Sabine Ponader; Jan A Burger
Journal:  J Clin Oncol       Date:  2014-04-28       Impact factor: 44.544

Review 8.  Toll-like receptor signaling in cell proliferation and survival.

Authors:  Xinyan Li; Song Jiang; Richard I Tapping
Journal:  Cytokine       Date:  2009-09-22       Impact factor: 3.861

Review 9.  Role of PIR-B in autoimmune glomerulonephritis.

Authors:  Toshiyuki Takai; Akira Nakamura; Shota Endo
Journal:  J Biomed Biotechnol       Date:  2010-10-04

Review 10.  Molecular mechanisms of regulation of Toll-like receptor signaling.

Authors:  Cynthia A Leifer; Andrei E Medvedev
Journal:  J Leukoc Biol       Date:  2016-06-24       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.